Table COn-study mortality

VariableDarbepoetin vs. EpoetinEpoetin vs. ControlDarbepoetin vs. ControlEpoetin or Darbepoetin vs. Control
Number of trials231637
Patients analyzed1,5678,6182,64811,266
Pooled HR (95% CI)0.901.19a1.051.17b
(0.67 to 1.20)(1.05 to 1.36)(0.80 to 1.38)(1.04 to 1.31)
I272%3%0%0%

CI = confidence interval; HR = hazard ratio

a

Excludes single trial enrolling pediatric patients.

b

Excludes single trial enrolling pediatric patients. Excluding 3 trials classified here as radiotherapy or predominantly radiotherapy yielded an HR of 1.16 (95% CI, 1.03 to 1.30).

From: Executive Summary

Cover of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment
Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment: Comparative Effectiveness Update [Internet].
Comparative Effectiveness Reviews, No. 113.
Grant MD, Piper M, Bohlius J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.